Tango Therapeutics, Inc.
NASDAQ:TNGX · NASDAQ Global Market
-$3.24 today
Vol 11.81M · Avg 3.67M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-29.3%
avg -72.6%
ROIC
-29.3%
avg -33.6%
ROA
-25.5%
avg -25.5%
Analysis
ROA is currently the strongest return metric at -25.5% versus its period average of -25.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Barbara L. Weber | Founder & Executive Chair | $1.24M | — | 69 | $1.63M | 1.31% |
Adam S. Crystal | President of Research & Development | $928,209.00 | — | 49 | $136,603.00 | 0.11% |
Daniella Beckman | Executive Officer | $765,152.00 | — | 47 | $184,410.00 | 0.15% |
Matthew Gall | Chief Financial Officer | $717,616.00 | — | 49 | $240,000.00 | 0.19% |
Malte Peters | President, Chief Executive Officer & Director | $148,315.00 | — | 64 | $1.65M | 1.33% |
Elizabeth Pingpank Hickin | Vice President of IR & Corporate Communications | — | — | — | — | — |
Julie Carretero | Chief Human Resources Officer | — | — | 53 | — | — |
Julie Fogarty | Vice President of Legal & Corporate Secretary | — | — | — | — | — |
Jannik N. Andersen | Chief Scientific Officer | — | — | — | — | — |
Michael Palmieri | Chief Technical Operations Officer | — | — | — | $0.00 | <0.01% |
Philippe Serrano | Chief Regulatory Officer | — | — | — | — | — |
Antoni Ribas | Founder & Member of Scientific Advisory Board | — | — | 59 | — | — |
William G. Kaelin Jr. | Founder & Member of Scientific Advisory Board | — | — | 68 | — | — |
Alan Ashworth | Founder & Member of Scientific Advisory Board | — | — | 65 | $190,181.00 | 0.15% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
22
$31.04M
Net Sentiment
$31.04M
Net selling
Most Active
Crystal Adam
11 transactions
1–10 of 22
Analysis
Insiders reported 0 buys worth $0.00 and 22 sells worth $31.04M over the last 12 months. That adds up to net selling of $31.04M. Crystal Adam was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +68.3% | +51.3% (7yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +68.3% over three years. Forward estimates point to Revenue at +51.3% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Kodiak Sciences Inc.
NASDAQ:KOD
$1.90B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.62B
Septerna, Inc.
NASDAQ:SEPN
$1.59B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.47B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.25B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.14B
Xencor, Inc.
NASDAQ:XNCR
$946.79M
Kura Oncology, Inc.
NASDAQ:KURA
$858.00M
ProKidney Corp.
NASDAQ:PROK
$262.71M
Who manages TNGX?
Tango Therapeutics, Inc. (TNGX) lists 14 active executives. The top listed executive is Matthew Gall, Chief Financial Officer.
Are TNGX insiders buying or selling?
Recent insider activity shows net selling of $11.92M.
Explore More
Continue the stock analysis
Jump to another research area for this company.